Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Home Page: www.acadia-pharm.com
ACAD Technical Analysis
12830 El Camino Real
San Diego,
CA
92130
United States
Phone:
858 558 2871
Officers
| Name | Title |
|---|---|
| Mr. Stephen R. Davis J.D. | CEO & Director |
| Dr. Srdjan R. Stankovic M.D., M.S.P.H. | Pres |
| Mr. Mark C. Schneyer | Exec. VP & CFO |
| Mr. Brendan P. Teehan | Exec. VP, COO & Head of Commercial |
| Mr. Austin D. Kim | Exec. VP, Gen. Counsel & Sec. |
| Mr. James K. Kihara | VP, Chief Accounting Officer & Corp. Controller |
| Mr. Bob Mischler | Sr. VP of Strategy & Technology Operations |
| Mr. Mark C. Johnson | VP of Investor Relations |
| Ms. Julie Fisher | Sr. VP of Marketing & Commercial Strategy |
| Mr. Rob Ackles | Sr. VP & Chief People Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.0027 |
| Price-to-Sales TTM: | 4.7708 |
| IPO Date: | 2004-05-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 510 |